Evidence Level
Vitamin D3 is supported by robust scientific evidence across various health outcomes. A landmark 2019 trial published in *The New England Journal of Medicine* (Manson et al., 2019) involving over 25,000 participants found that daily supplementation with 2,000 IU of vitamin D3 did not significantly reduce overall cancer incidence but decreased cancer mortality by 25% during follow-up. Additionally, a 2017 meta-analysis in *BMJ* (Martineau et al., 2017) of 25 randomized controlled trials demonstrated that vitamin D supplementation reduced the risk of acute respiratory infections, particularly in individuals with baseline 25(OH)D levels below 25 nmol/L.
Recent studies have further elucidated the benefits and limitations of vitamin D3. A systematic review by van den Heuvel et al. (2024) found that daily vitamin D3 supplementation more effectively raises total 25(OH)D levels compared to vitamin D2, with a weighted mean difference of -10.39 nmol/L (P < 0.0001). Furthermore, a 2024 meta-analysis by Tao et al. (2024) of 14 RCTs concluded that intermittent high-dose vitamin D3 increased serum levels but did not reduce falls, fractures, or mortality in elderly individuals.
In terms of bone health, a 2023 systematic review and meta-analysis by Manoj et al. (2023) involving seven RCTs with over 12,600 participants found that daily supplementation of 800 IU vitamin D3 plus 1200 mg calcium reduced hip fracture risk by 25% (OR=0.75; p=.0003). Another meta-analysis by Kazemian et al. (2023) across 39 studies demonstrated that vitamin D3 supplementation significantly increased bone mineral density at the lumbar spine and femoral neck, though effects were less pronounced at other sites.
Overall, vitamin D3 exhibits consistent benefits for immune function, cancer mortality reduction, and bone health, with emerging insights into optimal dosing strategies.